Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04058145
Title AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + Plerixafor

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02062 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field